ALNY vs NVS
ALNY: Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | ALNY | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $266.99 | $153.08 | |
| Market cap as of 2026-07-23 | $36.2B | $229.2B | |
| P/E as of 2026-07-23 | 62.77 | 22.11 | NVS lower |
| PEG as of 2026-07-23 | 1.11 | 3.66 | ALNY lower |
| Net margin as of 2026-07-23 | +13.5% | +22.5% | NVS higher |
| Gross margin as of 2026-07-23 | +80.8% | +75.0% | ALNY higher |
| Operating margin as of 2026-07-23 | +16.6% | +29.9% | NVS higher |
| ROE as of 2026-07-23 | +98.3% | +29.9% | ALNY higher |
| ROA as of 2026-07-23 | +11.8% | +11.1% | ALNY higher |
| Debt / equity as of 2026-07-23 | 2.52 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-07-23 | +82.6% | +3.3% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.0% | |
| Beta as of 2026-07-23 | 0.24 | 1.17 | |
| 1-year return as of 2026-07-22 close | -15.3% | +35.8% | NVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.